<DOC>
	<DOCNO>NCT02097433</DOCNO>
	<brief_summary>As part global clinical development program Dacomitinib , study plan cancer patient China . An assessment Dacomitinib pharmacokinetics Chinese subject , require Chinese Health Authorities , therefore warrant . The single 45 mg oral dose pharmacokinetics Dacomitinib characterize .</brief_summary>
	<brief_title>Dacomitinib ( PF-00299804 ) Pharmacokinetics In Chinese Healthy Volunteers</brief_title>
	<detailed_description>To evaluate pharmacokinetics Dacomitinib Chinese healthy volunteer .</detailed_description>
	<criteria>Healthy Chinese volunteer ( individual currently reside mainland China , born China , whose parent Chinese descent ) . Healthy male and/or female ( nonchildbearing potential ) subject age 18 45 year , inclusive . ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 19.0 24.0 kg/m2 ; total body weight 50 kg ( 110 lb ) . Evidence history clinically significant dermatologic , hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . Drug dependency , positive urine drug screen and/or alcohol dependency . Use tobacco nicotine containing product ( positive urine cotinine test ) . History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week men ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Treatment investigational drug biologic within last 3 month ( determined local requirement ) 5 halflives precede first dose study medication , whichever longer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Dacomitinib</keyword>
	<keyword>PF299804</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>healthy</keyword>
	<keyword>Chinese</keyword>
</DOC>